These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 36076888)

  • 41. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention.
    Yu SY; Xu L
    J Appl Microbiol; 2021 Aug; 131(2):564-582. PubMed ID: 33411984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease.
    Yu JS; Youn GS; Choi J; Kim CH; Kim BY; Yang SJ; Lee JH; Park TS; Kim BK; Kim YB; Roh SW; Min BH; Park HJ; Yoon SJ; Lee NY; Choi YR; Kim HS; Gupta H; Sung H; Han SH; Suk KT; Lee DY
    Clin Transl Med; 2021 Dec; 11(12):e634. PubMed ID: 34965016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota.
    Ji L; Deng H; Xue H; Wang J; Hong K; Gao Y; Kang X; Fan G; Huang W; Zhan J; You Y
    Compr Rev Food Sci Food Saf; 2023 Mar; 22(2):1128-1147. PubMed ID: 36717374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
    Zhao ZH; Lai JK; Qiao L; Fan JG
    J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease.
    Yu J; Zhang H; Chen L; Ruan Y; Chen Y; Liu Q
    Front Cell Infect Microbiol; 2021; 11():698852. PubMed ID: 34568090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis.
    Liu X; Sun R; Li Z; Xiao R; Lv P; Sun X; Olson MA; Gong Y
    Arch Biochem Biophys; 2021 Oct; 711():109019. PubMed ID: 34478730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
    Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
    Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gut microbiota-mitochondrial inter-talk in non-alcoholic fatty liver disease.
    Zhang Q; Xing W; Wang Q; Tang Z; Wang Y; Gao W
    Front Nutr; 2022; 9():934113. PubMed ID: 36204383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gut Microbiota and Lifestyle Interventions in NAFLD.
    Houghton D; Stewart CJ; Day CP; Trenell M
    Int J Mol Sci; 2016 Mar; 17(4):447. PubMed ID: 27023533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease.
    Mitsinikos FT; Chac D; Schillingford N; DePaolo RW
    Gut Microbes; 2020 Nov; 12(1):1-16. PubMed ID: 32816619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency.
    Liu L; Fu Q; Li T; Shao K; Zhu X; Cong Y; Zhao X
    PLoS One; 2022; 17(2):e0262855. PubMed ID: 35108315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
    Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
    J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the gut microbiota in NAFLD.
    Leung C; Rivera L; Furness JB; Angus PW
    Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective.
    Guo J; Shi CX; Zhang QQ; Deng W; Zhang LY; Chen Q; Zhang DM; Gong ZJ
    Therap Adv Gastroenterol; 2022; 15():17562848221138676. PubMed ID: 36506748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.